Cost-Effectiveness of Inhaled Nitric Oxide in the Treatment of Neonatal Respiratory Failure in the United States

PEDIATRICS ◽  
2003 ◽  
Vol 112 (6) ◽  
pp. 1351-1360 ◽  
Author(s):  
D. C. Angus ◽  
G. Clermont ◽  
R. S. Watson ◽  
W. T. Linde-Zwirble ◽  
R. H. Clark ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
United States ◽  
Cost Effectiveness ◽  
Respiratory Failure ◽  
The United States ◽  
Inhaled Nitric Oxide

Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn: Implications and Strategy for Future "High-Tech" Neonatal Clinical Trials

PEDIATRICS ◽  
1995 ◽  
Vol 96 (6) ◽  
pp. 1147-1151
Author(s):  
Ann R. Stark ◽  
Dennis Davidson
Keyword(s):  
Nitric Oxide ◽  
United States ◽  
Clinical Trials ◽  
Pulmonary Hypertension ◽  
The United States ◽  
Inhaled Nitric Oxide ◽  
Persistent Pulmonary Hypertension ◽  
High Tech ◽  
Widespread Application ◽  
Number Of Patients

Five large clinical trials are in progress in the United States and Canada examining the efficacy and safety of inhaled nitric oxide (iNO) for persistent pulmonary hypertension of the newborn (PPHN) and severe respiratory failure in near-term and term infants. A large trial in France that includes premature infants is also under way. Neonatologists have shown great interest in the use of iNO as a selective pulmonary vasodilator, but in the United States and perhaps elsewhere, widespread application of this treatment outside of study sites will have to await completion of clinical trials. At the current pace, we expect it will take several years to enroll an adequate number of patients to address relevant outcome end-points.

Cost-effectiveness of inhaled nitric oxide in near-term and term infants with respiratory failure: Eighteen- to 24-month follow-up for Canadian patients

2002 ◽  
Vol 30 (10) ◽  
pp. 2330-2334 ◽  
Author(s):  
Philip Jacobs ◽  
Neil N. Finer ◽  
Konrad Fassbender ◽  
Ed Hall ◽  
Charlene M. T. Robertson
Keyword(s):  
Nitric Oxide ◽  
Cost Effectiveness ◽  
Respiratory Failure ◽  
Inhaled Nitric Oxide ◽  
Term Infants ◽  
Near Term

scholarly journals Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States

2021 ◽  
Vol 24 (1) ◽  
pp. 421-431
Author(s):  
Claire L. Simons ◽  
Daniel Malone ◽  
Michael Wang ◽  
Gregory A. Maglinte ◽  
Tim Inocencio ◽  
...  
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
The United States ◽  
Adult Patients ◽  
Car T ◽  
Mantle Cell
Sign in / Sign up

Export Citation Format

Share Document